SABS · Company research
SAB Biotherapeutics, Inc. (SABS): Stock News & Events
Recent company-linked news records available in the database.
RESEARCH CONTEXT
Understand the numbers
Recent company-linked news records available in the database. Use period, currency, units and source fields when interpreting values.
16records availableHealthcare
Stock News & Events data
Database-backed records only
| title | summary | url | source | published at | sentiment | sentiment score | relevance score |
|---|---|---|---|---|---|---|---|
| A New York healthcare conference will feature SAB BIO's CEO in a fireside chat - Stock Titan | A New York healthcare conference will feature SAB BIO's CEO in a fireside chat Stock Titan | View source ↗ | Stock Titan | Oct 14, 2026 | neutral | 0 | 0.6 |
| SABS Q2 2026 Earnings: Narrower-Than-Expected Loss Fails to Lift Shares - Tech Earnings Analysis - https://www.dars.gov.et/ | SABS Q2 2026 Earnings: Narrower-Than-Expected Loss Fails to Lift Shares - Tech Earnings Analysis https://www.dars.gov.et/ | View source ↗ | https://www.dars.gov.et/ | Oct 13, 2026 | neutral | 0 | 0.6 |
| symbol__ Stock Quote Price and Forecast - CNN | symbol__ Stock Quote Price and Forecast CNN | View source ↗ | CNN | Oct 13, 2026 | neutral | 0 | 0.6 |
| Sab Biotherapeutics Inc (SABS-Q) Stock Price and News - The Globe and Mail | Sab Biotherapeutics Inc (SABS-Q) Stock Price and News The Globe and Mail | View source ↗ | The Globe and Mail | Oct 1, 2026 | neutral | 0 | 0.6 |
| Early data on a type 1 diabetes treatment include an insulin-production signal. - Stock Titan | Early data on a type 1 diabetes treatment include an insulin-production signal. Stock Titan | View source ↗ | Stock Titan | Oct 1, 2026 | neutral | 0 | 0.6 |
| SAB (SABS) Today: Posts a 2.16% Gain to $3.78 in the Current Update; Price Setup: the Current Price Sits Inside the Supplied Technical Range in the Latest Session - Momentum Trade - https://www.siam.in/ | SAB (SABS) Today: Posts a 2.16% Gain to $3.78 in the Current Update; Price Setup: the Current Price Sits Inside the Supplied Technical Range in the Latest Session - Momentum Trade https://www.siam.in/ | View source ↗ | https://www.siam.in/ | Aug 22, 2026 | neutral | 0 | 0.6 |
| SAB Biotherapeutics (SABS) Slides 3.4% as Stock Tests Key Support Levels - Unusual Put Volume - https://www.dars.gov.et/ | SAB Biotherapeutics (SABS) Slides 3.4% as Stock Tests Key Support Levels - Unusual Put Volume https://www.dars.gov.et/ | View source ↗ | https://www.dars.gov.et/ | Jul 19, 2026 | neutral | 0 | 0.6 |
| Barclays Assigns Overweight Rating to SAB Biotherapeutics Inc. (SABS) - Yahoo Finance | Barclays Assigns Overweight Rating to SAB Biotherapeutics Inc. (SABS) Yahoo Finance | View source ↗ | Yahoo Finance | Jun 30, 2026 | neutral | 0 | 0.6 |
| SABS Forecast — Price Target — Prediction for 2027 - TradingView | SABS Forecast — Price Target — Prediction for 2027 TradingView | View source ↗ | TradingView | Jun 26, 2026 | neutral | 0 | 0.6 |
| Is SAB Biotherapeutics (NASDAQ:SABS) In A Good Position To Deliver On Growth Plans? - Simply Wall Street | Is SAB Biotherapeutics (NASDAQ:SABS) In A Good Position To Deliver On Growth Plans? Simply Wall Street | View source ↗ | Simply Wall Street | Jun 2, 2026 | neutral | 0 | 0.6 |
| SABS - Finviz | SABS Finviz | View source ↗ | Finviz | May 29, 2026 | neutral | 0 | 0.6 |
| We Think SAB Biotherapeutics (NASDAQ:SABS) Needs To Drive Business Growth Carefully - Yahoo Finance | We Think SAB Biotherapeutics (NASDAQ:SABS) Needs To Drive Business Growth Carefully Yahoo Finance | View source ↗ | Yahoo Finance | May 15, 2026 | neutral | 0 | 0.6 |
| $SABS ($SABS) Releases Q1 2026 Earnings - Quiver Quantitative | $SABS ($SABS) Releases Q1 2026 Earnings Quiver Quantitative | View source ↗ | Quiver Quantitative | May 12, 2026 | neutral | 0 | 0.6 |
| MRNA, INO, SABS, NVAX Stocks Jump Premarket: Deadly Hantavirus Reaches US After Cruise Ship Outbreak - Stocktwits | MRNA, INO, SABS, NVAX Stocks Jump Premarket: Deadly Hantavirus Reaches US After Cruise Ship Outbreak Stocktwits | View source ↗ | Stocktwits | May 11, 2026 | neutral | 0 | 0.6 |
| SAB Biotherapeutics Looks Undervalued If SAB-142 Delivers In Type 1 Diabetes - Seeking Alpha | SAB Biotherapeutics Looks Undervalued If SAB-142 Delivers In Type 1 Diabetes Seeking Alpha | View source ↗ | Seeking Alpha | Apr 15, 2026 | neutral | 0 | 0.6 |
| SAB Biotherapeutics, Inc. Common Stock (SABS) Stock Price: Oct 12 Close $2.83 - Gotrade | SAB Biotherapeutics, Inc. Common Stock (SABS) Stock Price: Oct 12 Close $2.83 Gotrade | View source ↗ | Gotrade | Mar 14, 2026 | neutral | 0 | 0.6 |
Informational research only, not financial advice. Forecasts are uncertain and can be wrong.